Characterization of potential drug targets farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase in Schistosoma mansoni

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5969-5976

  Ziniel, Peter D ^a,b   Desai, Janish ^c   Cass, Cynthia L ^a   Gatto, Craig ^a   Oldfield, Eric ^c,d   Williams, David L ^a,b  

^a ILLINOIS STATE UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FARNESYL TRANS TRANSFERASE; GERANYLTRANSFERASE; ANTHELMINTIC AGENT; ENZYME INHIBITOR; HELMINTH PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; DRUG TARGETING; EX VIVO STUDY; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SURVIVAL; WORM; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IC50; KINETICS; MALE; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; SOLUBILITY;

AMINO ACID SEQUENCE; ANIMALS; ANTHELMINTICS; DIPHOSPHONATES; ENZYME INHIBITORS; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GERANYLTRANSTRANSFERASE; HELMINTH PROTEINS; INHIBITORY CONCENTRATION 50; KINETICS; MALE; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SCHISTOSOMA MANSONI; SEQUENCE HOMOLOGY, AMINO ACID; SOLUBILITY; SUBSTRATE SPECIFICITY;

EID: 84887458904     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00699-13     Document Type: Article

References (53)

1. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. 2009. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373: 1570-1575.
2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. 2006. Schistosomiasis and water resources development: systematic review, metaanalysis, and estimates of people at risk. Lancet Infect. Dis. 6:411-425.
3. Wang W, Wang L, Liang YS. 2012. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol. Res. 111:1871-1877.
4. Dömling A, Khoury K. 2010. Praziquantel and schistosomiasis. ChemMedChem 5:1420-1434.
5. Mutapi F, Billingsley PF, Secor WE. 2013. Infection and treatment immunizations for successful parasite vaccines. Trends Parasitol. 29:135-141.
6. Chen GZ, Foster L, Bennett JL. 1990. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme A reductase activity in Schistosoma mansoni is vital for parasite survival. Naunyn Schmiedebergs Arch. Pharmacol. 342:477-482.
7. Edwards PA, Ericsson J. 1999. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68:157-185.
8. Clarke S. 1992. Protein isoprenylation and methylation at carboxylterminal cysteine residues. Annu. Rev. Biochem. 61:355-386.
9. Oldfield E. 2010. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Acc. Chem. Res. 43:1216-1226.
10. Oldfield E, Lin FY. 2012. Terpene biosynthesis: modularity rules. Angew. Chem. Int. Ed. Engl. 51:1124-1137.
11. Shafer WR, Rine J. 1992. Protein prenylation: genes, enzymes, targets, and functions. Annu. Rev. Genet. 30:209-237.
12. Meyer F, Meyer H, Bueding E. 1970. Lipid metabolism in the parasitic and free-living flatworms, Schistosoma mansoni and Dugesia dorotocephala. Biochim. Biophys. Acta 210:257-266.
13. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, Mashiyama ST, Al-Lazikani B, Andrade LF, Ashton PD, Aslett MA, Bartholomeu DC, Blandin G, Caffrey CR, Coghlan A, Coulson R, Day TA, Delcher A, DeMarco R, Djikeng A, Eyre T, Gamble JA, Ghedin E, Gu Y, Hertz-Fowler C, Hirai H, Hirai Y, Houston R, Ivens A, Johnston DA, Lacerda D, Macedo CD, McVeigh P, Ning Z, Oliveira G, Overington JP, Parkhill J, Pertea M, Pierce RJ, Protasio AV, Quail MA, Rajandream MA, Rogers J, Sajid M, Salzberg SL, Stanke M, Tivey AR, White O, Williams DL, Wortman J, Wu W, Zamanian M, Zerlotini A, Fraser-Liggett CM, Barrell BG, El-Sayed NM. 2009. The genome of the blood fluke Schistosoma mansoni. Nature 460:352-358.
14. Vandewaa EA, Mills G, Chen GZ, Foster LA, Bennett JL. 1989. Physiological role of HMG-CoA reductase in regulating egg production by Schistosoma mansoni. Am. J. Physiol. 257:R618-R625.
15. Rajkovic A, Simonsen JN, Davis RE, Rottman FM. 1989. Molecular cloning and sequence analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase from the human parasite Schistosoma mansoni. Proc. Natl. Acad. Sci. U. S. A. 86:8217-8221.
16. Chen GZ, Bennett JL. 1993. Characterization of mevalonate-labeled lipids isolated from parasite proteins in Schistosoma mansoni. Mol. Biochem. Parasitol. 59:287-292.
17. Foster JM, Pennock JF, Marshall I, Rees HH. 1993. Biosynthesis of isoprenoid compounds in Schistosoma mansoni. Mol. Biochem. Parasitol. 61:275-284.
18. Osman A, Niles EG, LoVerde PT. 1999. Characterization of the Ras homologue of Schistosoma mansoni. Mol. Biochem. Parasitol. 100:27-41.
19. Loeffler IK, Bennett JL. 1996. A rab-related GTP-binding protein in Schistosoma mansoni. Mol. Biochem. Parasitol. 77:31-40.
20. Vermeire JJ, Osman A, LoVerde PT, Williams DL. 2003. Characterisation of a Rho homologue of Schistosoma mansoni. Int. J. Parasitol. 33:721-731.
21. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J. 1980. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl- coenzyme A reductase and a cholesterollowering agent. Proc. Natl. Acad. Sci. U. S. A. 77:3957-3961.
22. Brown MS, Faust JR, Goldstein JL. 1978. Inhibition of 3-hydroxy 3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 253:1121-1128.
23. Brown MS, Goldstein JL. 1986. A receptor mediated pathway for cholesterol homeostasis. Science 232:34-47.
24. Araújo N, Mattos AC, Sarvel AK, Coelho PM, Katz N. 2008. Oxamniquine, praziquantel and lovastatin association in the experimental Schistosomiasis mansoni. Mem. Inst. Oswaldo Cruz 103:450-454.
25. Russell RG. 2006. Bisphosphonates: from bench to bedside. Ann. N. Y. Acad. Sci. 1068:367-401.
26. Martin MB, Grimley JS, Lewis JC, Heath HT, 3rd, Bailey BN, Kendrick H, Yardley V, Caldera A, Lira R, Urbina JA, Moreno SN, Docampo R, Croft SL, Oldfield E. 2001. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44:909-916.
27. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Séronie-Vivien S. 2006. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6:60. doi:10.1186/1471-2407-6-60.
28. Ashburn TT, Thor KB. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3:673-683.
29. Martin MB, Sanders JM, Kendrick H, de Luca-Fradley K, Lewis JC, Grimley JS, Van Brussel EM, Olsen JR, Meints GA, Burzynska A, Kafarski P, Croft SL, Oldfield E. 2002. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J. Med. Chem. 45:2904-2914.
30. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R. 2001. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. J. Biol. Chem. 276:33930-33937.
31. Montalvetti A, Fernandez A, Sanders JM, Ghosh S, Van Brussel E, Oldfield E, Docampo R. 2003. Farnesyl diphosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J. Biol. Chem. 278:17075-17083.
32. Moreno B, Bailey BN, Luo S, Martin MB, Kuhlenschmidt M, Moreno SN, Docampo R, Oldfield E. 2001. (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. Biochem. Biophys. Res. Commun. 284:632-637.
33. Ghosh S, Chan JM, Lea CR, Meints GA, Lewis JC, Tovian ZS, Flessner RM, Loftus TC, Bruchhaus I, Kendrick H, Croft SL, Kemp RG, Kobayashi S, Nozaki T, Oldfield E. 2004. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J. Med. Chem. 47:175-187.
34. Moreno SN, Li ZH. 2008. Anti-infectives targeting the isoprenoid pathway of Toxoplasma gondii. Expert Opin. Ther. Targets 12:253-263.
35. Jordão FM, Saito AY, Miguel DC, de Jesus Peres V, Kimura EA, Katzin AM. 2011. In vitro and in vivo antiplasmodial activity of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob. Agents Chemother. 55:2026-2031.
36. Mukkamala D, No JH, Cass LM, Chang TK, Oldfield E. 2008. Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. J. Med. Chem. 51:7827-7833.
37. Singh AP, Zhang Y, No JH, Docampo R, Nussenzweig V, Oldfield E. 2010. Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth. Antimicrob. Agents Chemother. 54:2987-2993.
38. Lewis F. 2001. Schistosomiasis. Curr. Protoc. Immunol. Chapter 19:Unit 19.1. doi:10.1002/0471142735.im1901s28.
39. Sagami H, Morita Y, Ogura K. 1994. Purification and properties of geranylgeranyl-diphosphate synthase from bovine brain. J. Biol. Chem. 269:20561-20566.
40. Ericsson J, Greene JM, Carter KC, Shell BK, Duan DR, Florence C, Edwards PA. 1998. Human geranylgeranyl diphosphate synthase: isolation of the cDNA, chromosomal mapping and tissue expression. J. Lipid Res. 39:1731-1739.
41. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arnér ES, Williams DL. 2007. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 4:e206. doi:10.1371/journal.pmed.0040206.
42. Tarshis LC, Yan M, Poulter CD, Sacchettini JC. 1994. Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-A resolution. Biochemistry 33:10871-10877.
43. Kawasaki T, Hamano Y, Kuzuyama T, Itoh N, Seto H, Dairi T. 2003. Interconversion of the product specificity of type I eubacterial farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase through one amino acid substitution. J. Biochem. 133:83-91.
44. Li ZH, Cintron R, Koon NA, Moreno SN. 2012. The N-terminus and the chain-length determination domain play a role in the length of the isoprenoid product of the bifunctional Toxoplasma gondii farnesyl diphosphate synthase. Biochemistry 51:7533-7540.
45. Hemmi H, Noike M, Nakayama T, Nishino T. 2003. An alternative mechanism of product chain-length determination in type III geranylgeranyl diphosphate synthase. Eur. J. Biochem. 270:2186-2194.
46. Wiemer AJ, Tong H, Swanson KM, Hohl RJ. 2007. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem. Biophys. Res. Commun. 353:921-925.
47. Kelley LA, Sternberg MJE. 2009. Protein structure prediction on the web: a case study using the Phyre server. Nat. Protoc. 4:363-371.
48. Mekkriengkrai D, Sando T, Hirooka K, Sakdapipanich J, Tanaka Y, Fukusaki E, Kobayashi A. 2004. Cloning and characterization of farnesyl diphosphate synthase from the rubber-producing mushroom Lactarius chrysorrheus. Biosci. Biotechnol. Biochem. 68:2360-2368.
49. Artz JD, Wernimont AK, Dunford JE, Schapira M, Dong A, Zhao Y, Lew J, Russell RG, Ebetino FH, Oppermann U, Hui R. 2011. Molecular characterization of a novel geranylgeranyl diphosphate synthase from Plasmodium parasites. J. Biol. Chem. 286:3315-3322.
50. Artz JD, Dunford JE, Arrowood MJ, Dong A, Chruszcz M, Kavanagh KL, Minor W, Russell RG, Ebetino FH, Oppermann U, Hui R. 2008. Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. Chem. Biol. 15:1296-1306.
51. Glickman JF, Schmid A. 2007. Farnesyl diphosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay. Assay Drug Dev. Technol. 5:205-214.
52. Zhang Y, Cao R, Yin F, Hudock MP, Guo RT, Krysiak K, Mukherjee S, Gao YG, Robinson H, Song Y, No JH, Bergan K, Leon A, Cass L, Goddard A, Chang TK, Lin FY, Van Beek E, Papapoulos S, Wang AH, Kubo T, Ochi M, Mukkamala D, Oldfield E. 2009. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J. Am. Chem. Soc. 131:5153-5162.
53. Zhang Y, Cao R, Yin F, Lin FY, Wang H, Krysiak K, No JH, Mukkamala D, Houlihan K, Li J, Morita CT, Oldfield E. 2010. Lipophilic pyridinium bisphosphonates: potent γδ T cell stimulators. Angew. Chem. Int. Ed. Engl. 49:1136-1138.